•
Oct 02, 2020

Danaher Q3 2020 Earnings Report

Danaher reported outstanding third quarter results, achieving double-digit revenue growth and over 60% adjusted EPS growth, while more than doubling their free cash flow year-over-year.

Key Takeaways

Danaher Corporation announced strong Q3 2020 results, with a 34.5% increase in revenues to $5.9 billion and a 62.0% increase in non-GAAP adjusted diluted net earnings per common share to $1.72. The company also saw a 93.0% increase in operating cash flow and a 110.0% increase in non-GAAP free cash flow.

Net earnings were $883.5 million, or $1.16 per diluted common share, a 38.0% year-over-year increase.

Non-GAAP adjusted diluted net earnings per common share were $1.72, a 62.0% increase year-over-year.

Revenues increased 34.5% year-over-year to $5.9 billion, with 14.0% non-GAAP core revenue growth including Cytiva.

Operating cash flow was $1.7 billion, a 93.0% increase year-over-year, and non-GAAP free cash flow was $1.5 billion, a 110.0% increase year-over-year.

Total Revenue
$5.88B
Previous year: $5.04B
+16.8%
EPS
$1.72
Previous year: $1.16
+48.3%
Core Sales Growth
14%
Gross Profit
$3.23B
Previous year: $2.81B
+14.9%
Cash and Equivalents
$5.69B
Previous year: $14.3B
-60.1%
Free Cash Flow
$1.5B
Previous year: $784M
+91.4%
Total Assets
$72.9B
Previous year: $61.5B
+18.5%

Danaher

Danaher

Forward Guidance

For the fourth quarter 2020, the Company anticipates that non-GAAP core revenue growth including Cytiva will be in the low-double digit range.